MedTrace Logo

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

NCT07096999 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-07-31

No results posted yet for this study

Summary

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Conditions

  • Metastatic Castration-Resistant Prostate Carcinoma

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Yuni K Dewaraja · University of Michigan Rogel Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2031-01-23
Completion
2031-01-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07096999 on ClinicalTrials.gov